On March 26, 2018 – Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported that results from multiple preclinical studies of its Lm-based antigen delivery technology will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 (AACR 2018), April 14-18, 2018 in Chicago (Press release, Advaxis, MAR 26, 2018, View Source [SID1234524983]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following late-breaking research will be presented:

Poster Title:

Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform
Poster Number:

LB-150/17
Session Title:

Late-Breaking Research: Clinical Research
Session Date and Time:

Monday, April 16, 2018, 1:00 pm – 5:00 pm (CT)
Authored By:

Advaxis and Amgen

Poster Title:

Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific antitumor immunity in the MC38 and CT26 mouse tumor models

Poster Number:

LB-148/15
Session Title:

Late-Breaking Research: Clinical Research
Session Date and Time:

Monday, April 16, 2018, 1:00 pm – 5:00 pm (CT)
Authored By:

Advaxis and Amgen

Poster Title:

Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induces potent anti-tumor immunity

Poster Number:

LB-149/16
Session Title:

Late-Breaking Research: Clinical Research
Session Date and Time:

Monday, April 16, 2018, 1:00 pm – 5:00 pm (CT)
Authored By:

Advaxis

In addition, the following Investigator Sponsored Trial data will be presented:

Poster Title:

Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer
Poster Number:

5639/10
Session Title:

PO.CL06.11: Vaccines 2
Session Date and Time:

Wednesday, April 18, 2018, 8:00 am – 12:00 pm (CT)
Authored By:

Andrew Sikora, Ph.D., MD, co-director of the Head and Neck Cancer Program at Baylor College of Medicine